Kyntra Bio is singularly focused on advancing a mid-to late-stage pipeline of treatments for cancer and anemia associated with lower-risk myelodysplastic syndromes.
Our near-term priorities include:
Execution of the Phase 2 trial of FG-3246 and FG-3180 for mCRPC.
Initiation of a Phase 3 registrational study of roxadustat in anemia associated with LR-MDS in patients with high transfusion burden.
Explore Our Pipeline
We are developing products with the potential to change lives.
